Overview
- Description
Herantis Pharma Plc is focusing on clinical-stage biotechnology disease modifying therapies for neurodegenerative diseases. For the past two years the Company has solely focused on HER-096 development which is an advanced small synthetic chemical peptidomimetic molecule to treat Parkinson’s disease through a subcutaneous administration, enabling to modify and slow the disease progression in early stages. If successful, HER-096 may become a global blockbuster in the structurally growing Parkinson’s disease drug market projected to be USD 11.5bn by 2029 (the US, EU5, Japan).
- Website
- Country
- Finland
- Theme
- Healthcare